When Zhao Hong, chief doctor of China’s leading cancer hospital at the Chinese Academy of Medical Sciences, told his fellow delegates at a Communist Party meeting in March that a little-known Guangzhou biotech firm’s cancer drug had beaten the world’s bestselling medicine, investors took notice.

Adv

📰

Continue Reading on South China Morning Post

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →